The in vitro heparin sensitivity of 6 different commercial activated partial thromboplastin time (APTT) reagents was investigated based on artificial plasma samples prepared by addition of sodium heparin at different activities (0—1.5 IU/ml) to pooled normal canine plasma. Statistical analysis using 2-way analysis of variance was based on APTT ratios (APTT/mean APTT control). Significant differences between the APTT ratios of different APTT reagents (P < 0.00001) were found, which also depended on heparin activity (interaction between the factors; P < 0.00001). For example, mean APTT ratio at 0.7 IU/ml heparin varied between 1.2 and 2.5. The results of this study indicate that recommendations for the control of heparin therapy in dogs by APTT ratio should be reagent specific.
References
1.
BakerBAAdelmanMDSmithPAOsborneJC: 1997, Inability of the activated partial thromboplastin time to predict heparin levels. Time to assess guidelines for heparin assays. Arch Intern Med157:2475–2479.
2.
BasuDGallisAHirshJ: 1972, A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med287:324–327.
3.
BrigdenMLJohnstonM: 2000, A survey of APTT reporting in Canadian Medical Laboratories: the need for increased standardization. Am J Clin Pathol114:276–282.
4.
D'AngeloASevesoMPD'AngeloSV: 1990, Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol94:297–306.
5.
GawoskiJMArkinCFBovillT: 1987, The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists survey specimens: responsiveness, precision, and sample effects. Arch Pathol Lab Med111:785–790.
6.
GreenRA: 1980, Activated partial thromboplastin time in monitoring heparinized dogs. Am J Vet Res11:1793–1797.
7.
HaushoferAHalbmayerWMFischerM: 1997. Überwachung der Heparintherapie mit der aktivierten partiellen Thromboplastinzeit (APTT)—Voraussetzungen und klinische. Bedeutung. Ellipse13:79–84.
8.
HellebrekersLJSlappendelRJVan den BromWE: 1985, Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog. Am J Vet Res46:1460–1462.
9.
KitchenSPrestonFE: 1996, The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemostasis75:734–797.
10.
MischkeR: 2001, Optimization of coagulometric tests that incorporate human plasma for determination of coagulation factor activities in canine plasma. Am J Vet Res62:625–629.
11.
MischkeRJacobsC: 2001, The monitoring of heparin administration by screening tests in experimental dogs. Res Vet Sci70:101–108.
12.
PollerLThomsonJMTabernerDA: 1989, Use of the activated partial thromboplastin time for monitoring heparin therapy: problems and possible solutions. Ric Clin Lab19:363–370.
13.
ReedSVHaddonMEDensonKWE: 1994: An attempt to standardize the APTT for heparin monitoring, using the P.T. ISI/INR system of calibration. Results of a 13 centre study. Thromb Res74:515–522.
14.
RosboroughTK: 1997, Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol108:662–668.
15.
RosboroughTK: 1998, Comparing different lots of activated partial thromboplastin time. Am J Clin Pathol110:173–177.
16.
ShapiroGAHuntzingerSWWilsonJE: 1977, Variation among commercial activated partial thromboplastin time reagents in response to heparin. Am J Clin Pathol67:477–480.
17.
ShojaniaAMTetreaultJTurnbullG: 1988, The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol89:19–23.
18.
Van den BesselaarAMMeeuwisse-BraunJBertinaRM: 1990, Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemostasis63:16–23.
19.
Van der VeldeEAPollerL: 1995, The APTT monitoring of heparin—the ISTH/ICSH collaborative study. Thromb Haemostasis73:73–81.
20.
ZimmermannRSpringerSHarenbergJ: 1987, Laboratory control of heparin and thrombolytic therapy by thrombin clotting time and partial thromboplastin time. Ärztl Lab33:121–126.
